CY1117051T1 - Φαρμακευτικες συνθεσεις που περιεχουν κρυσταλλικη μορφη (i) της υδροχλωριουχου λερκανιδιπινης - Google Patents

Φαρμακευτικες συνθεσεις που περιεχουν κρυσταλλικη μορφη (i) της υδροχλωριουχου λερκανιδιπινης

Info

Publication number
CY1117051T1
CY1117051T1 CY20151101129T CY151101129T CY1117051T1 CY 1117051 T1 CY1117051 T1 CY 1117051T1 CY 20151101129 T CY20151101129 T CY 20151101129T CY 151101129 T CY151101129 T CY 151101129T CY 1117051 T1 CY1117051 T1 CY 1117051T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical compositions
hydrochloride
lerkanidipin
compositions containing
crystal form
Prior art date
Application number
CY20151101129T
Other languages
English (en)
Inventor
Fausto Bonifacio
Original Assignee
Recordati Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11448245&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1117051(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Recordati Ireland Limited filed Critical Recordati Ireland Limited
Publication of CY1117051T1 publication Critical patent/CY1117051T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

Η εφεύρεση αναφέρεται σε αντιυπερτασικές φαρμακευτικές συνθέσεις που περιλαμβάνουν κρυσταλλική μορφή (I) υδροχλωριούχου λερκανιδιπίνης.
CY20151101129T 2001-08-06 2015-12-10 Φαρμακευτικες συνθεσεις που περιεχουν κρυσταλλικη μορφη (i) της υδροχλωριουχου λερκανιδιπινης CY1117051T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001MI001726A ITMI20011726A1 (it) 2001-08-06 2001-08-06 Forme polimorfe della lercanidipina cloridrato
EP09174609.9A EP2157083B1 (en) 2001-08-06 2002-08-05 Pharmaceutical compositions containing crystalline form (I) of lercanidipine hydrochloride

Publications (1)

Publication Number Publication Date
CY1117051T1 true CY1117051T1 (el) 2017-04-05

Family

ID=11448245

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20101100011T CY1109711T1 (el) 2001-08-06 2010-01-05 Νεα κρυσταλλικη μορφη υδροχλωριουχου λερκανιδιπινης και διαδικασιες για την παρασκευη τους
CY20151101129T CY1117051T1 (el) 2001-08-06 2015-12-10 Φαρμακευτικες συνθεσεις που περιεχουν κρυσταλλικη μορφη (i) της υδροχλωριουχου λερκανιδιπινης

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20101100011T CY1109711T1 (el) 2001-08-06 2010-01-05 Νεα κρυσταλλικη μορφη υδροχλωριουχου λερκανιδιπινης και διαδικασιες για την παρασκευη τους

Country Status (36)

Country Link
EP (4) EP1600441B1 (el)
JP (1) JP2005504045A (el)
KR (3) KR100626819B1 (el)
CN (2) CN101475524B (el)
AP (1) AP1766A (el)
AR (1) AR037139A1 (el)
AT (2) ATE307114T1 (el)
AU (1) AU2002327924C1 (el)
BR (1) BR0211739A (el)
CY (2) CY1109711T1 (el)
DE (2) DE60234961D1 (el)
DK (3) DK2157083T3 (el)
EA (1) EA005673B1 (el)
EC (1) ECSP044973A (el)
ES (3) ES2212759T3 (el)
HK (3) HK1067123A1 (el)
HR (1) HRP20040156B1 (el)
HU (1) HU229563B1 (el)
IL (3) IL153917A (el)
IT (1) ITMI20011726A1 (el)
MA (1) MA27133A1 (el)
ME (2) ME01525B (el)
MX (1) MXPA04001069A (el)
NO (2) NO325541B1 (el)
NZ (2) NZ531558A (el)
OA (1) OA12648A (el)
PE (1) PE20030328A1 (el)
PL (1) PL216066B1 (el)
PT (2) PT1600441E (el)
RS (1) RS52161B (el)
SI (3) SI1432683T1 (el)
TN (1) TNSN04024A1 (el)
UA (1) UA82988C2 (el)
UY (1) UY27410A1 (el)
WO (1) WO2003014084A1 (el)
ZA (1) ZA200401806B (el)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20011726A1 (it) 2001-08-06 2003-02-06 Recordati Ind Chimica E Farma Forme polimorfe della lercanidipina cloridrato
AR043395A1 (es) * 2003-02-28 2005-07-27 Recordati Ireland Ltd Terapia de combinacion para la hipertension utilizando lercanidipina y un bloqueante de los receptores de angiotensina ii
DE04801160T1 (de) * 2003-12-01 2007-08-09 Lifecycle Pharma A/S Pharmazeutische zusammensetzungen mit lercanidipin
AR052918A1 (es) 2005-02-25 2007-04-11 Recordati Ireland Ltd Clorhidrato de lercanidipina amorfo
US8097729B2 (en) 2005-09-16 2012-01-17 Glenmark Generics Ltd. Polymorphic form of lercanidipine hydrochloride and process for the preparation thereof
KR100821165B1 (ko) * 2006-03-10 2008-04-14 동우신테크 주식회사 레르카니디핀 염산염의 제조 방법
US20110040097A1 (en) * 2006-12-29 2011-02-17 Dongwoo Syntech Co., Ltd Process for preparing lercanidipine hydrochloride
EP2121575A2 (en) * 2007-03-05 2009-11-25 Actavis Group PTC EHF Lercanidipine hydrochloride polymorphs and an improved process for preparation of 1,1,n-trimethyl-n-(3,3-diphenylpropyl)-2-aminoethyl acetoacetate
EP2585051B2 (en) 2010-06-23 2020-04-08 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts
EP2444394A1 (en) 2010-10-21 2012-04-25 Alembic Pharmaceuticals Limited Process for the preparation of amorphous form of lercanidipine HCI
WO2012085249A2 (en) 2010-12-24 2012-06-28 Krka, D.D., Novo Mesto Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts
EP2700632A4 (en) * 2011-04-18 2014-09-03 Hefei Beini Medical Technology Company Ltd METHOD FOR CLEANING DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS AND PRODUCING NANOPARTICLES THEREFOR
CN102558032B (zh) * 2011-12-16 2014-02-26 华润赛科药业有限责任公司 一种无定形盐酸乐卡地平及其制备方法
CN102531999B (zh) * 2011-12-16 2014-02-26 华润赛科药业有限责任公司 无定形盐酸乐卡地平及其制备方法
CN102584682A (zh) * 2011-12-31 2012-07-18 苏州二叶制药有限公司 盐酸乐卡地平的制备方法
CN103497075B (zh) * 2013-09-25 2016-03-23 山西北化关铝化工有限公司 水悬浮延期药造型粉
CN109232389B (zh) * 2018-05-15 2021-10-08 迪嘉药业集团有限公司 一种小粒度硝苯地平的结晶制备方法
CN115353485B (zh) * 2022-07-26 2024-04-19 山西双雁药业有限公司 从硝苯地平母液中回收硝苯地平的方法及应用
CN115671066A (zh) * 2022-11-21 2023-02-03 安徽宏业药业有限公司 一种盐酸乐卡地平缓释片及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US596139A (en) * 1897-12-28 Process of generating acetylene gas
GB8403866D0 (en) 1984-02-14 1984-03-21 Recordati Chem Pharm Diphenylalkylaminoalkyl esters
IT1275532B (it) * 1995-07-14 1997-08-07 Recordati Chem Pharm Uso di derivati 1,4-diidropiridinici per la prevenzione e la terapia della degenerazione aterosclerotica della parete arteriosa
US5696139A (en) 1995-05-12 1997-12-09 Recordati S.A., Chemical And Pharmaceutical Company Use of S-enantiomers of 1,4-dihydropyridine derivatives for treating heart failure
IT1274480B (it) * 1995-05-12 1997-07-17 Recordati Chem Pharm Procedimento migliorato per la preparazione della lercanidipina cloridrato
US5912351A (en) 1995-05-12 1999-06-15 Recordati, S.A. Chemical And Pharmaceutical Company Anhydrous 1,4-Dihydropyridines and salts thereof
WO2001060806A2 (en) 2000-02-16 2001-08-23 Neurogen Corporation Substituted arylpyrazines
ITMI20011726A1 (it) 2001-08-06 2003-02-06 Recordati Ind Chimica E Farma Forme polimorfe della lercanidipina cloridrato
US20040198789A1 (en) 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations

Also Published As

Publication number Publication date
DK1432683T3 (da) 2006-03-06
UA82988C2 (uk) 2008-06-10
PL369522A1 (en) 2005-05-02
NO325541B1 (no) 2008-06-16
TNSN04024A1 (en) 2006-06-01
EP1432683B9 (en) 2006-01-18
HK1086263A1 (en) 2006-09-15
IL164648A0 (en) 2005-12-18
MXPA04001069A (es) 2005-02-17
CN100448847C (zh) 2009-01-07
EP2157083A3 (en) 2010-03-24
ECSP044973A (es) 2004-06-28
AP1766A (en) 2007-08-10
ATE307114T1 (de) 2005-11-15
ME01525B (me) 2011-02-10
DE60206787D1 (de) 2006-03-02
EP1432683B1 (en) 2005-10-19
EP1600441A3 (en) 2005-12-07
ATE453624T1 (de) 2010-01-15
CN101475524B (zh) 2012-08-29
HU229563B1 (en) 2014-02-28
CN1538957A (zh) 2004-10-20
AP2004002989A0 (en) 2004-03-31
CN101475524A (zh) 2009-07-08
CY1109711T1 (el) 2014-08-13
ES2555213T3 (es) 2015-12-29
MA27133A1 (fr) 2005-01-03
UY27410A1 (es) 2003-03-31
DK1600441T3 (da) 2010-02-08
NO20082330L (no) 2004-03-24
IL153917A (en) 2005-11-20
HRP20040156B1 (en) 2012-03-31
EP1600441A2 (en) 2005-11-30
EP2157083B1 (en) 2015-09-30
IL164648A (en) 2007-02-11
KR20050043992A (ko) 2005-05-11
SI1432683T1 (sl) 2006-04-30
WO2003014084A1 (en) 2003-02-20
HK1140487A1 (en) 2010-10-15
IL153917A0 (en) 2003-07-31
NO335651B1 (no) 2015-01-19
PT2157083E (pt) 2016-01-22
EP2036890A1 (en) 2009-03-18
EA005673B1 (ru) 2005-04-28
PT1600441E (pt) 2010-01-20
JP2005504045A (ja) 2005-02-10
NZ541341A (en) 2007-02-23
DK2157083T3 (en) 2015-11-02
SI1600441T1 (sl) 2010-02-26
DE60206787T2 (de) 2006-07-13
KR100667687B1 (ko) 2007-01-12
NZ531558A (en) 2005-12-23
BR0211739A (pt) 2004-09-28
EP1432683A1 (en) 2004-06-30
OA12648A (en) 2006-06-16
ITMI20011726A0 (it) 2001-08-06
NO20040266L (no) 2004-03-24
HUP0401163A3 (en) 2009-04-28
ITMI20011726A1 (it) 2003-02-06
MEP2908A (en) 2010-10-10
EP1600441B1 (en) 2009-12-30
ES2212759T1 (es) 2004-08-01
RS52161B (en) 2012-08-31
AU2002327924B2 (en) 2008-04-24
DE60234961D1 (de) 2010-02-11
ES2212759T3 (es) 2006-04-16
AR037139A1 (es) 2004-10-27
ES2334678T3 (es) 2010-03-15
HUP0401163A2 (hu) 2004-09-28
PL216066B1 (pl) 2014-02-28
KR100626819B1 (ko) 2006-09-20
KR20050111799A (ko) 2005-11-28
EP2157083A2 (en) 2010-02-24
EA200400280A1 (ru) 2004-08-26
KR20040030903A (ko) 2004-04-09
PE20030328A1 (es) 2003-05-09
SI2157083T1 (sl) 2016-01-29
ZA200401806B (en) 2005-06-29
AU2002327924C1 (en) 2009-12-10
HRP20040156A2 (en) 2004-08-31
HK1067123A1 (en) 2005-04-01
RS11304A (en) 2007-02-05

Similar Documents

Publication Publication Date Title
CY1117051T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν κρυσταλλικη μορφη (i) της υδροχλωριουχου λερκανιδιπινης
CY1117639T1 (el) Φαρμακευτικες συνθεσεις βασιζομενες επι κρυσταλλικης μορφης i της 5-αζακυτιδινης
CY1122429T1 (el) Αμορφη υδροχλωρικη λερκανιδιπινη
SE9904652D0 (sv) Novel Compounds
SE0101675D0 (sv) Novel composition
IS7220A (is) Latar af þætti XA og öðrum rað-próteösum sem tengjast storknunar keðjuverkun
DE69919397D1 (de) Thrombin-inhibitoren
NO20050741L (no) Ny fremgangsmate for syntesen og ny krystallinsk form av agomelatin og farmasoytiske sammensetninger inneholdende den
CY1107634T1 (el) Φαρμακευτικη συνθεση
DK1427415T3 (da) Forbindelser indeholdende lactam og derivater heraf som faktor Xa-hæmmere
EA200300937A1 (ru) Оральная фармацевтическая композиция цефподоксима проксетила
DE60334773D1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
DK1522539T3 (da) Krystallinsk komposition indeholdende excitalopram
DK1385515T3 (da) Spiropyrazole forbindelser
EA200300334A1 (ru) Новая соль периндоприла и содержащие ее фармацевтические композиции
PT1458377E (pt) Composicoes farmaceuticas contendo tegaserod
TNSN06012A1 (en) Emulsifying systems containing azetidine derivatives
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
DK1892239T3 (da) Inhibitorer af cytosol-phospholipase A2
CY1108224T1 (el) Καινοτομες κρυσταλλικες μορφες ενος αναστολεα του παραγοντα χα
ATE416214T1 (de) Zusammensetzungen enthaltend lipid-polymer konjugate
NO20062022L (no) 1-(kinolinamino)- og 1-(isokinolinamino)-substituerte pentan-2-oler, fremgangsmate for fremstilling av disse og anvendelse av den som antiinflammatoriske midler
CY1105798T1 (el) Στepοειδη, η παρασκευη τους, φαρμακευτικες συνθεσεις απο αυτα και χρησεις των ενωσεων
BRPI0417205A (pt) composições farmacêuticas
ATE328595T1 (de) Carvedilolpolymorph